Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()

INTRODUCTION: The presence of KRAS mutations in patients with metastatic colorectal cancer (mCRC) predicts poor response to agents targeting the EGFR. Even in patients with RAS wild type (WT) tumors, resistance eventually develops due to multiple mechanisms, including the expansion of previously und...

Descripción completa

Detalles Bibliográficos
Autores principales: Matikas, Alexios, Voutsina, Alexandra, Lagoudaki, Eleni, Hatzidaki, Dora, Trypaki, Maria, Stoupis, Giannis, Tzardi, Maria, Mavroudis, Dimitrios, Georgoulias, Vasilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503828/
https://www.ncbi.nlm.nih.gov/pubmed/28692881
http://dx.doi.org/10.1016/j.tranon.2017.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503828/
https://www.ncbi.nlm.nih.gov/pubmed/28692881
http://dx.doi.org/10.1016/j.tranon.2017.06.005

Ejemplares similares